Argenx Bvba

Argenx Bv

Universitè Catholique De Louvain

Ludwig Institute for Cancer Research Limited

Universiteit Gent

Vib Vzw

Argen-x N.v.

Argenx Iip Bv

Université Catholique De Louvian

Sebastian Paul Van Der Woning

Michael Saunders

Torsten Dreier

Christophe Blanchetot

Pierre G Coulie

Sophie Lucas

Gitte De Boeck

Johannes Joseph Wilhelmus De Haard

Hans De Haard

Christophe Frederic Jerome Blanchetot

Natalie De Jonge

Filip Borgions

Lore Mariën

Tine Skak-Nielsen

Birgitte Ursø

Malene Bertelsen

Jean-Christophe Renauld

Johannes De Haard

Laure Dumoutier

Bart Lambrecht

Savvas Savvides

Hamida Hammad

Kenneth Verstraete

Julia Cuende Villasur

Stéphanie Liénart

Nicolas Ongenae

Jean-Michel Percier

Emma Persson

Stëphanie Liénart

The present invention relates to bispecific and other multispecific antigen binding constructs. In certain aspects, the invention relates to bispecific antigen binding constructs comprising a single domain antibody (VHH) antigen binding region fused to an IgG Fc domain; a heavy chain-Fc domain portion of a conventional IgG antibody, and a light chain portion of a conventional IgG antibody. The bispecific antigen binding constructs of the invention are capable of targeting two different antigens separately or in a protein complex.

Bispecific antigen binding construct

The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

IL-6 binding molecules

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Galectin-10 antibodies

The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Anti-IL-22R antibodies

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-&#x3b2;1, particularly a complex of human GARP and human TGF-&#x3b2;1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-&#x3b2; from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Nucleic acids encoding GARP-TGF-beta 1 antibodies

GARP-TGF-&#x3b2; 1 IGG antibodies

Antibody against a complex between human GARP and latent TGF-&#x3b2;

GARP-TGF-beta 1 antibodies

Growing community of inventors

Ghent, Belgium

Sebastian Paul Van Der Woning